Tata Sons-Backed MedTherapy Establishes India Manufacturing Hub for CAR-T Cell and Gene Therapies
核心洞察
MedTherapy (搜索), funded by Tata Sons (搜索), operates as a contract development and manufacturing organization (CDMO) with facilities in Boston and New Delhi to reduce CAR-T therapy production costs and timelines.
The company has developed manufacturing platforms that can produce CAR-T therapies in one day compared to several weeks for industry standard, targeting both blood cancers and solid tumors.
MedTherapy (搜索) collaborates with 22 global academic institutes including Harvard University and has partnerships with Cipla for cell and gene therapy development in India.
Tata Sons (搜索)-funded biotech company MedTherapy (搜索) is positioning India as a global manufacturing hub for cell and gene therapies through its contract development and manufacturing organization (CDMO) model, aiming to dramatically reduce costs and production timelines for advanced cancer treatments.
The US-based company, which operates technology facilities in Boston and manufacturing operations in New Delhi NCR, has developed manufacturing platforms that can produce CAR-T cell therapies in just one day compared to several weeks required by industry standards, according to CEO Dr. Bikash Verma, who previously served as medical director and faculty at Harvard University Medical School and at Novartis.
Manufacturing Innovation Addresses Industry Crisis
CAR-T cell therapy, first approved by the US FDA in 2017, has shown clinical responses across multiple cancer indications but faces significant manufacturing constraints that limit accessibility and affordability globally. MedTherapy (搜索)'s integrated manufacturing model addresses these challenges by providing efficient, compliant manufacturing of both viral vectors and CAR-T cell therapy products at dramatically reduced costs and timelines.
"The current manufacturing crisis faced by the CAR-T cell therapy industry in particular and the cell and gene therapy industry in general is a global crisis," Verma stated. "Our integrated manufacturing model ameliorates all the major constraints and provides efficient, compliant and speedy manufacturing of both viral vectors and CAR-T cell therapy products at global scales."
Comprehensive Pipeline and Partnerships
MedTherapy (搜索) operates two distinct business units: a CDMO service for manufacturing CAR-T cell therapies and viral vectors for other companies, and co-development of its own CAR-T therapy products. The company's oncology pipeline includes CAR-T therapies targeting blood cancers and solid tumors including brain, breast, lung, skin, and bone cancers.
The company collaborates with 22 global academic institutes across India, the US, Canada, and Europe, including Harvard University. A notable partnership with Indian pharmaceutical company Cipla focuses on developing cell and gene therapy for the Indian market, though specific details remain undisclosed.
Clinical Progress and Global Expansion
MedTherapy (搜索)'s blood cancer CAR-T therapy program has completed clinical studies in the US and is preparing for clinical trials in India. According to the company, this therapy has demonstrated "one of the best response rates and safety profile among lymphoma patients" while being manufactured in just one day.
The company's co-development efforts have produced "very promising armored CAR-T therapies for solid tumors including brain, breast, lung, skin and bone cancers entering global clinical trials," representing a significant advancement in treating traditionally difficult-to-target solid tumors.
Strategic Vision for India
Founded in the US in 2018 and incorporated in India in 2020, MedTherapy (搜索) received support from the late Ratan Tata in bringing breakthrough cancer therapies to India. The company's strategy aims to leverage India's technical manpower and manufacturing capabilities to establish the country as a global gene therapy manufacturing hub.
Dr. Dinesh Pendharkar, a leading oncologist in India, endorsed MedTherapy (搜索)'s CDMO approach, stating: "World is moving ahead in the field of cell and gene therapy with unbelievable speed. India will only be able to match if we organize our manufacturing sector building CDMO like MedTherapy in this field."
The company's CDMO services span the entire development spectrum from discovery and pre-clinical stages through clinical and commercial production, offering next-generation manufacturing platforms, viral vectors, and full-spectrum end-to-end manufacturing services with dramatically reduced costs and timelines.
Kewal Handa, former MD of Pfizer India and former Chairman of Union Bank of India, endorsed MedTherapy (搜索)'s dual strategy as both a CDMO and pipeline developer, noting its potential to become a "billion dollar company" while serving patients globally with impressive returns on investment.